As advised via PHARMAC Tender Results of 31 July 2019 there is to be a change in the listing and future sole supply of Metoclopramide Injection.

Change from 1 October 2019 (price & subsidy decrease)

Metoclopramide Hyd Inj Pfizer 5 mg per ml, 2 ml 10 ampoule pack                         Pharmacode 771759                      Schedule price $9.50

Incumbent brand delisting 1 January 2020                                                                       Metoclopramide Inj Link S29 5 mg per ml, 2 ml 10 ampoule pack                         Pharmacode 2567393                       Schedule price $13.56

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 January 2020.

Brand switch fee not notified in July 2019 Tender.

As of the date of this notification ProPharma / PWR cannot accept Metoclopramide Inj Link for credit under any circumstances.

Due to the Incumbent being Section 29 we cannot implement automatic substitution.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both products listed and fully funded until the commencement of the sole supply 1 January 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author